Cover Image

HARDBACK
$52.95



View/Hide Left Panel

COST INCURRED BY DISEASE

Table A5–1 summarizes the health care costs incurred by ETEC infections. For the purposes of the calculations in this report, it was assumed that all people infected with ETEC use over-the-counter medications and that only a small fraction see a physician. Costs for additional diapers and oral rehydration are included for some of the infected individuals, whether travelers or not. It is these costs which are increased for those who experience a more prolonged diarrhea.

VACCINE DEVELOPMENT

The estimates for the model are that it will take 7 years until licensure and that $240 million needs to be invested. Table 4–1 summarizes vaccine development assumptions for all vaccines considered in this report.

VACCINE PROGRAM CONSIDERATIONS

Target Population

The target population was estimated to include the annual birth cohort and overseas travelers. For the purposes of this report, the number of targeted travelers is 2,500,000 annually. It is estimated that 90% of infants and 30% of travlers will receive the immunization.

Vaccine Schedule, Efficacy, and Costs

The committee estimated that this vaccine would cost $50 per dose and that vaccine administration would cost an additional $10. The committee has accepted default assumptions for this vaccine that it will require a series of 3 doses and that efficacy will be 75%. Table 4–1 summarizes vaccine program assumptions for all vaccines considered in this report.

RESULTS

If a vaccine program for ETEC were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the QALYs gained would be 1,600. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the QALYs gained would be 280.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement